z-logo
Premium
Return of inactivated whole‐virus vaccine for superior efficacy
Author(s) -
Furuya Yoichi
Publication year - 2012
Publication title -
immunology and cell biology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.999
H-Index - 104
eISSN - 1440-1711
pISSN - 0818-9641
DOI - 10.1038/icb.2011.70
Subject(s) - virology , virus , pandemic , outbreak , influenza vaccine , immunity , reverse vaccinology , biology , influenza a virus , immune system , immunology , vaccination , dna vaccination , epitope , medicine , antibody , immunization , covid-19 , infectious disease (medical specialty) , disease , pathology
The swine, influenza, H1N1 outbreak in 2009 highlighted the inadequacy of the currently used antibody‐based vaccine strategies as a preventive measure for combating influenza pandemics. The ultimate goal for successful control of newly arising influenza outbreaks is to design a single‐shot vaccine that will provide long‐lasting immunity against all strains of influenza A virus. A large amount of data from animal studies has indicated that the cross‐reactive cytotoxic T (Tc) cell response against conserved influenza virus epitopes may be the key immune response needed for a universal influenza vaccine. However, decades of research have shown that the development of safe T‐cell‐based vaccines for influenza is not an easy task. Here, I discuss the overlooked but potentially highly advantageous inactivation method, namely, γ‐ray irradiation, as a mean to reach the Holy Grail of influenza vaccinology.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom